How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

The F-35 fighter jets operated by the U.S. Air Force and the Japan Air Self-Defense Force are equipped with software coded in C++. This C++ code is written in accordance with a coding standard called ...

Hepatitis C is liver inflammation and damage caused by infection with the hepatitis C virus. Hep C can cause a mild illness that lasts a short time (acute) or a serious illness that can last the rest ...

Lauren (Hansen) Holznienkemper is a lead editor for the small business vertical at Forbes Advisor, specializing in HR, payroll and recruiting solutions for small businesses. Using research and writing ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Harvard's free programming classes teach you how to think, debug, and adapt in an AI-driven world where knowing code matters more than ever.